| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.10. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.10.2026 | 461 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 20.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.10.2026ISIN NameBMG7403L1046 REALORD... ► Artikel lesen | |
| 13.10. | XFRA 651: AUSSETZUNG/SUSPENSION | 352 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLIFECLEAN INTL AB... ► Artikel lesen | |
| 06.10. | Lifeclean International AB Q3 Loss Drops | 1 | RTTNews | ||
| 28.09. | LifeClean International AB (publ) - Removal from trading on Nasdaq First North Growth Market | 342 | GlobeNewswire | LifeClean International AB (publ) has applied for its shares to be removed from trading on Nasdaq First North Growth Market.
Nasdaq Stockholm AB has approved the application and decided to... ► Artikel lesen | |
| 15.06. | LifeClean International AB (publ) receives observation status | 454 | GlobeNewswire | Today, June 15, 2026, LifeClean International AB (publ) (the "Company") issued a press release with information that the Company's board of directors had resolved to apply for delisting of the Company's... ► Artikel lesen | |
| LIFECLEAN INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 18.03. | Listing of units rights and paid subscription units of Lifeclean International AB | 435 | GlobeNewswire | With effect from March 19, 2026, the units rights in Lifeclean International AB will be traded on First North Growth Market. Trading will continue up until and including March 30, 2026.
... ► Artikel lesen | |
| 13.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 13.03.2026 | 921 | Xetra Newsboard | Das Instrument OUH3 CA96041W2076 WESTKAM GOLD EQUITY wird cum Kapitalmassnahme gehandelt am 13.03.2026 und ex Kapitalmassnahme am 16.03.2026 The instrument OUH3 CA96041W2076 WESTKAM GOLD EQUITY is traded... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 43,050 | +0,37 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| UNITEDHEALTH | 370,60 | +0,49 % | UnitedHealth Group To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Tuesday | ||
| INMODE | 12,165 | +0,45 % | InMode Ltd. - 6-K, Report of foreign issuer | ||
| NETRAMARK | 0,350 | -7,41 % | NetraMark Holdings Inc.: NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness | TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical... ► Artikel lesen | |
| SIENNA SENIOR LIVING | 12,600 | +0,80 % | Dividendenbekanntmachungen (15.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5648 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1096 CAD 0,069 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY | 2,140 | 0,00 % | Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349% | Revenue rose 31.1% to RMB 632 million, while net profit increased 47.8% to RMB 179 millionHANGZHOU, China, Aug. 20, 2026 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX:... ► Artikel lesen | |
| SCANDINAVIAN REAL HEART | 1,395 | 0,00 % | Scandinavian Real Heart AB: Peer-Reviewed Study Shows Six Times Lower Blood Damage in Realheart TAH Than Market-Leading Device in Vitro | Västerås, Sweden, September 16, 2026 - Scandinavian Real Heart AB (publ) announces today that a study sponsored by the company has been published in the peer-reviewed journal Nature Scientific Reports... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 60,34 | +0,20 % | BrightSpring Health Services, Inc. Bottom Line Rises In Q3 | ||
| LIFESTANCE HEALTH GROUP | 13,635 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 8,020 | -0,50 % | Alignment Healthcare Q3 2026 Earnings Call Transcript | ||
| FRESENIUS MEDICAL CARE | 40,920 | -1,33 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat FMC auf "Underweight" mit einem Kursziel von 32,30 Euro belassen. Entgegen seinen Erwartungen seien die Konsensschätzungen an die Quartalszahlen... ► Artikel lesen | |
| HEARTFLOW | 60,55 | +0,03 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| BILLIONTOONE | 114,75 | -0,08 % | BillionToOne, Inc.: BillionToOne's Tissue-Free Northstar Response Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds | MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| FRESENIUS | 47,570 | +1,21 % | BERENBERG stuft Fresenius SE auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Fresenius von 50 auf 54 Euro angehoben und die Einstufung auf "Buy" belassen. Der Markt bewerte den Medizinkonzern als vom... ► Artikel lesen | |
| GENEDX | 70,98 | -0,06 % | GeneDx plans to add long-read genome sequencing to portfolio |